-
Propranolol delays tumour growth and increases survival when combined with immunotherapy
europeanpharmaceuticalreview
January 10, 2018
A common, inexpensive drug that is used to prevent heart attacks and lower blood pressure may also help melanoma patients live longer…
-
Higher mutational burdens in tumours linked to greater immunotherapy success, study finds
pharmafile
December 22, 2017
New research from the Johns Hopkins Kimmel Cancer Center and its Bloomberg-Kimmel Cancer Institute for Cancer Immunotherapy has indicated that the mutational burden can provide a strong indicator as to whether a cancer will respond to checkpoint inhibito
-
FDA approves Foundation Medicine’s FoundationOne CDx, the first pan-tumour comprehensive genomic pro
roche
December 05, 2017
Roche Corporation announced today that the FDA has approved the FoundationOne CDx ? Foundation's comprehensive companion diagnostic method for personalized oncology treatment1
-
Roche launches NAVIFY Tumor Board solution to provide decision support to oncology care teams
worldpharmanews
October 10, 2017
Roche has announced the launch of the NAVIFY Tumor Board solution, a clinical workflow and decision support software that optimises decision-making for cancer patient case reviews in tumor boards, or multi-disciplinary team meetings.
-
Notable Labs nets $10M funding for personalized cancer treatment techNotable Labs nets $10M funding
biospectrumasia
September 08, 2017
The company comes up with a report of the results, which an oncologist will use to guide treatment decisions for the patient
-
FDA approves first cancer treatment for any solid tumor with a specific biomarker
europeanpharmaceuticalreview
May 25, 2017
The US Food and Drug Administration (FDA) granted accelerated approval to a treatment for patients whose cancers have a specific genetic feature (biomarker).
-
Immune Pharma Enters a Research Partnership
contractpharma
January 25, 2017
Will develop mono- and bispecific antibodies against tumors